Department of Pediatrics and Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
AIDS Behav. 2011 Aug;15(6):1121-7. doi: 10.1007/s10461-010-9741-9.
With the advent of highly active antiretroviral therapy (HAART) HIV-infected children are surviving into adulthood. Despite emerging evidence of the benefits of disclosure, when and how to disclose the diagnosis of HIV to children remain a clinical dilemma. We investigated the prevalence and determinants of HIV disclosure in a cross-sectional study of 71 caregiver-child dyads from the Pediatric HIV/AIDS Care Program at Korle-Bu Teaching Hospital (Accra, Ghana). The children were between 8 and 14 years of age (median age, 10.39 years). The prevalence of disclosure was 21%. In the unadjusted analyses, the age of child, the level of education of child, deceased biologic father, administration of own HIV medications, and longer duration on HIV medication were significantly associated with disclosure. The low prevalence of disclosure underscores the need for a systematic and a staged approach in disclosing HIV status to infected children in resource limited countries.
随着高效抗逆转录病毒疗法 (HAART) 的出现，HIV 感染的儿童得以存活至成年。尽管越来越多的证据表明披露的好处，但何时以及如何向儿童披露 HIV 诊断仍然是一个临床难题。我们对来自科勒布教学医院儿科 HIV/AIDS 护理计划 (加纳阿克拉) 的 71 对照顾者-儿童进行了横断面研究，调查了 HIV 披露的流行情况和决定因素。这些儿童年龄在 8 至 14 岁之间（中位数年龄为 10.39 岁）。披露率为 21%。在未调整的分析中，儿童的年龄、儿童的教育水平、已故亲生父亲、自行服用 HIV 药物以及服用 HIV 药物的时间长短与披露显著相关。披露率低突出表明，在资源有限的国家向感染儿童系统地和分阶段披露 HIV 状况非常有必要。
